Skip Navigation LinksHome > February 2010 - Volume 38 - Issue 2 > Feasibility, efficacy, and safety of antipsychotics for inte...
Critical Care Medicine:
doi: 10.1097/CCM.0b013e3181c58715
Clinical Investigations

Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebo-controlled trial*

Girard, Timothy D. MD, MSCI; Pandharipande, Pratik P. MD, MSCI; Carson, Shannon S. MD; Schmidt, Gregory A. MD; Wright, Patrick E. MD; Canonico, Angelo E. MD; Pun, Brenda T. MSN; Thompson, Jennifer L. MPH; Shintani, Ayumi K. PhD, MPH; Meltzer, Herbert Y. MD; Bernard, Gordon R. MD; Dittus, Robert S. MD, MPH; Ely, E Wesley MD, MPH; for the MIND Trial Investigators

Collapse Box

Abstract

Objective: To demonstrate the feasibility of a placebo-controlled trial of antipsychotics for delirium in the intensive care unit and to test the hypothesis that antipsychotics would improve days alive without delirium or coma.

Design: Randomized, double-blind, placebo-controlled trial.

Setting: Six tertiary care medical centers in the US.

Patients: One hundred one mechanically ventilated medical and surgical intensive care unit patients.

Intervention: Patients were randomly assigned to receive haloperidol or ziprasidone or placebo every 6 hrs for up to 14 days. Twice each day, frequency of study drug administration was adjusted according to delirium status, level of sedation, and side effects.

Measurements and Main Outcomes: The primary end point was the number of days patients were alive without delirium or coma. During the 21-day study period, patients in the haloperidol group spent a similar number days alive without delirium or coma (median [interquartile range], 14.0 [6.0–18.0] days) as did patients in the ziprasidone (15.0 [9.1–18.0] days) and placebo groups (12.5 [1.2–17.2] days; p = 0.66). No differences were found in secondary clinical outcomes, including ventilator-free days (p = .25), hospital length of stay (p = .68), and mortality (p = .81). Ten (29%) patients in the haloperidol group reported symptoms consistent with akathisia, compared with six (20%) patients in the ziprasidone group and seven (19%) patients in the placebo group (p = .60), and a global measure of extrapyramidal symptoms was similar between treatment groups (p = .46).

Conclusions: A randomized, placebo-controlled trial of antipsychotics for delirium in mechanically ventilated intensive care unit patients is feasible. Treatment with antipsychotics in this limited pilot trial did not improve the number of days alive without delirium or coma, nor did it increase adverse outcomes. Thus, a large trial is needed to determine whether use of antipsychotics for intensive care unit delirium is appropriate.

Trial Registration: ClinicalTrials.gov, number NCT00096863.

© 2010 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.